Mineralys Therapeutics (NASDAQ:MLYS) Releases Quarterly Earnings Results, Misses Expectations By $0.30 EPS

Mineralys Therapeutics (NASDAQ:MLYS) posted its quarterly earnings data on Monday. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30), Zacks reports. During the same quarter in the previous year, the firm posted ($0.57) EPS.

Mineralys Therapeutics Stock Down 10.3 %

NASDAQ:MLYS opened at $13.38 on Wednesday. The firm’s fifty day simple moving average is $12.95 and its 200-day simple moving average is $12.64. Mineralys Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $16.91.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a report on Tuesday.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the transaction, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Jon Congleton sold 15,271 shares of Mineralys Therapeutics stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the completion of the transaction, the chief executive officer now directly owns 895,941 shares in the company, valued at $12,113,122.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction on Friday, October 11th. The stock was sold at an average price of $13.57, for a total value of $145,972.49. Following the transaction, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at $3,214,108.78. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,510 shares of company stock worth $735,431 over the last 90 days. Company insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.